Elite Journal of HIV. Volume 2 issue 3(2024), Pp. 55-68
https://epjournals.com/journals/EJHIV

Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Gastrointestinal (GI) complications are prevalent among individuals living with HIV, contributing significantly to morbidity and affecting their overall quality of life. Antacids, commonly employed for managing acid-related disorders, have emerged as potential agents for preventing and managing GI complications in HIV patients. This review aims to provide a comprehensive overview of the literature on the efficacy, safety, and clinical implications of antacid therapy in this population. HIV infection predisposes individuals to a spectrum of GI complications, including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), gastritis, and infectious diarrhea, which significantly impact their well-being and treatment adherence. Antacids, including proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), are frequently prescribed to alleviate GI symptoms by reducing gastric acid secretion. Despite their efficacy in non-HIV populations, their role in managing GI complications in HIV patients remains poorly understood. The pathogenesis of GI complications in HIV involves a complex interplay of viral effects, immune dysregulation, microbial translocation, and opportunistic infections. Immune suppression associated with HIV increases susceptibility to infections such as cytomegalovirus (CMV) colitis and Cryptosporidium parvum enteritis, leading to chronic diarrhea and malabsorption. Moreover, immune reconstitution inflammatory syndrome (IRIS) upon initiating antiretroviral therapy (ART) may exacerbate pre-existing GI conditions or unveil subclinical infections, necessitating tailored management strategies. In HIV patients, antacids may play a crucial role in preventing and managing GI complications by attenuating acid-related mucosal damage and modulating gut microbiota. However, the efficacy and safety of antacid therapy in this population remain ambiguous, necessitating further investigation. Antacids represent a potential therapeutic option for preventing and managing GI complications in HIV patients.
Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

However, further research is warranted to establish their efficacy, safety, and optimal utilization in this population. Clinicians should exercise caution and individualize treatment decisions based on patient characteristics and clinical context. Future studies should aim to address existing knowledge gaps and refine treatment strategies to improve GI outcomes in HIV patients.

Keywords: *Antacids, Gastrointestinal Complications, HIV, Prevention, Management, Gastric Acid Suppression, Opportunistic Infections, Immune Reconstitution Inflammatory Syndrome, Nutritional Status, Adverse Effects.*

Introduction

Gastrointestinal (GI) complications represent a significant burden in individuals living with Human Immunodeficiency Virus (HIV), contributing to morbidity and impaired quality of life. The intricate interplay between HIV infection and GI health manifests in various disorders such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), gastritis, and opportunistic infections leading to diarrhea and malabsorption. These complications not only exacerbate existing symptoms but also pose challenges in treatment adherence and overall disease management. Amidst therapeutic interventions, the role of antacids has emerged as a potential avenue for both prevention and management of GI complications in HIV patients. Antacids, including proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), are commonly prescribed to mitigate gastric acid secretion and alleviate symptoms associated with acid-related disorders. While their efficacy is well-established in the general population, their utility in the context of HIV-associated GI complications remains relatively understudied. The complex pathophysiology of GI disorders in HIV, influenced by viral effects, immune dysregulation, and opportunistic infections, underscores the need for tailored therapeutic strategies that address the unique challenges faced by HIV patients. Despite the potential benefits, the use of antacids in HIV patients necessitates careful consideration of various factors, including drug interactions, adverse effects, and long-term safety. Concerns have been raised regarding the impact of antacid therapy on drug absorption, particularly in the context of antiretroviral therapy (ART), which forms the cornerstone of HIV management. Moreover, the risk of enteric infections and alterations in gut microbiota dynamics associated with antacid use warrant cautious prescribing practices and ongoing monitoring in HIV patients.[1-31]

Mechanisms of GI Complications in HIV

The mechanisms underlying gastrointestinal (GI) complications in individuals infected with Human Immunodeficiency Virus (HIV) are multifactorial and often involve complex interactions between the virus, host immune responses, opportunistic infections, and other factors. Understanding these mechanisms is crucial for effective management and prevention of GI issues in HIV patients. Firstly, HIV directly targets CD4+ T lymphocytes, which play a crucial role in maintaining gut mucosal integrity and immune function. The depletion of CD4+ T cells within the gut-associated lymphoid tissue (GALT) leads to mucosal barrier dysfunction, allowing for

microbial translocation. This process contributes to chronic immune activation and inflammation in the GI tract, which are hallmark features of HIV infection and can exacerbate existing GI conditions or predispose individuals to new complications. Secondly, opportunistic infections are common in HIV patients due to the compromised immune system. Pathogens such as cytomegalovirus (CMV), Cryptosporidium parvum, and Mycobacterium avium complex (MAC) can directly infect the GI tract, leading to conditions such as colitis, enteritis, and diarrhea. These infections can cause mucosal damage, inflammation, and malabsorption, further exacerbating GI symptoms and impairing nutritional status. Thirdly, alterations in gut microbiota composition and diversity are observed in HIV-infected individuals, which can contribute to GI complications. HIV infection is associated with dysbiosis, characterized by shifts in microbial communities and reductions in beneficial bacteria. Dysbiosis may disrupt gut homeostasis, impair mucosal barrier function, and exacerbate inflammation, predisposing individuals to GI symptoms such as diarrhea, bloating, and abdominal pain. Fourthly, immune reconstitution inflammatory syndrome (IRIS) can occur in HIV patients initiating antiretroviral therapy (ART), leading to exacerbation of pre-existing GI conditions or unmasking of subclinical infections. As ART restores immune function and CD4+ T cell counts, paradoxical inflammatory responses may occur, resulting in worsening GI symptoms. IRIS-related GI complications can include immune-mediated colitis, pancreatitis, and hepatobiliary disorders. Finally, lifestyle factors such as smoking, alcohol consumption, poor dietary habits, and medication use (including non-steroidal anti-inflammatory drugs and certain antiretroviral agents) can also contribute to GI complications in HIV patients. These factors may exacerbate inflammation, disrupt gut microbiota, and impair mucosal healing, thereby exacerbating existing GI conditions or increasing susceptibility to infections.[32-57]

Role of Antacids in Prevention and Management

Antacids play a significant role in the prevention and management of gastrointestinal (GI) complications in individuals living with Human Immunodeficiency Virus (HIV). These medications, including proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), are commonly used to reduce gastric acid secretion and alleviate symptoms associated with acid-related disorders. Antacids can help prevent mucosal injury caused by excess gastric acid production, reducing the risk of conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and gastritis. By suppressing gastric acid secretion, antacids promote mucosal healing and alleviate symptoms such as heartburn, dyspepsia, and regurgitation, thereby improving overall quality of life for HIV patients. HIV patients may experience GERD and reflux symptoms due to a variety of factors, including immune dysfunction, opportunistic infections, and medication side effects. Antacids provide symptomatic relief by reducing acid reflux and alleviating associated symptoms such as heartburn, chest pain, and regurgitation. By improving symptom control, antacids can enhance patient comfort and adherence to antiretroviral therapy (ART), thereby optimizing treatment outcomes.[58-80]

HIV patients are at increased risk of peptic ulcers, particularly due to factors such as stress, medication use, and co-infection with Helicobacter pylori. Antacids help prevent peptic ulcers by

reducing gastric acid secretion and promoting mucosal healing. By preventing ulcer formation and complications such as bleeding and perforation, antacids can reduce the need for invasive interventions and hospitalizations, leading to cost savings and improved patient outcomes. HIV patients initiating ART may experience immune reconstitution inflammatory syndrome (IRIS), characterized by paradoxical worsening of pre-existing conditions or unmasking of subclinical infections. Antacids can help alleviate GI symptoms associated with IRIS, such as abdominal pain, diarrhea, and dyspepsia, by reducing gastric acid secretion and mitigating mucosal inflammation. By providing symptomatic relief, antacids support adherence to ART and facilitate successful immune reconstitution, ultimately improving long-term outcomes for HIV patients. In addition to their role in managing acid-related disorders, antacids may have adjuvant effects in the management of opportunistic infections affecting the GI tract. By reducing gastric acidity, antacids may create a less hospitable environment for pathogens such as Helicobacter pylori, cytomegalovirus (CMV), and Candida species, potentially enhancing the efficacy of antimicrobial therapy and promoting resolution of infection.[81-103]

Evidence Supporting Efficacy

The evidence supporting the efficacy of antacids in the prevention and management of gastrointestinal (GI) complications in individuals living with Human Immunodeficiency Virus (HIV) is derived from a combination of clinical trials, observational studies, and expert consensus recommendations. Antacids exert their therapeutic effects by reducing gastric acid secretion and promoting mucosal healing, thereby preventing and managing mucosal injury associated with acid-related disorders. Although specific studies evaluating mucosal healing in HIV patients are scarce, evidence from studies in non-HIV populations supports the ability of antacids to promote ulcer healing and reduce the risk of complications such as bleeding and perforation. HIV patients may experience GI symptoms that adversely affect adherence to antiretroviral therapy (ART), leading to suboptimal treatment outcomes and disease progression. Antacids can help alleviate GI symptoms such as heartburn, reflux, and dyspepsia, thereby improving patient comfort and adherence to ART. Improved treatment adherence has been associated with better virological and immunological outcomes in HIV patients, highlighting the potential indirect benefits of antacid therapy. While direct evidence is limited, theoretical considerations suggest that antacids may have adjuvant effects in the management of opportunistic infections affecting the GI tract in HIV patients. By reducing gastric acidity, antacids create a less hospitable environment for pathogens such as Helicobacter pylori, cytomegalovirus (CMV), and Candida species, potentially enhancing the efficacy of antimicrobial therapy and promoting resolution of infection. Expert consensus guidelines, such as those developed by the Infectious Diseases Society of America (IDSA) and the European AIDS Clinical Society (EACS), recommend the use of antacids for the prevention and management of GI complications in HIV patients. While these recommendations are based on expert opinion and extrapolation from studies in non-HIV populations, they provide valuable guidance for clinicians in managing GI issues in HIV patients.[104-107]

Conclusion

Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

The evidence supporting the efficacy of antacids in the prevention and management of gastrointestinal (GI) complications in individuals living with Human Immunodeficiency Virus (HIV) underscores their valuable role in clinical practice. While direct evidence from randomized controlled trials specifically targeting antacid therapy in HIV patients is limited, extrapolation from studies in non-HIV populations and expert consensus recommendations support their use in this population. Antacids, including proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), have demonstrated efficacy in providing symptomatic relief, promoting mucosal healing, and improving quality of life in patients with acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD). By reducing gastric acid secretion and alleviating symptoms such as heartburn, regurgitation, and dyspepsia, antacids can improve patient comfort and adherence to antiretroviral therapy (ART), ultimately optimizing treatment outcomes and disease management in HIV patients.

References

1. Basile FW, Fedele MC, Lo Vecchio A. Gastrointestinal Diseases in Children Living with HIV. Microorganisms. 2021;9(8):1572.
2. Wilcox CM, Saag MS. Gastrointestinal complications of HIV infection: changing priorities in the HAART era. Gut. 2008;57(6):861-70.
3. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human immunodeficiency virus-associated diarrhea: still an issue in the era of antiretroviral therapy. Digestive diseases and sciences. 2015; 60:2236-2245.
4. Balderson BH, Grothaus L, Harrison RG, McCoy K, Mahoney C, Catz S. Chronic illness burden and quality of life in an aging HIV population. AIDS care. 2013;25(4):451-8.
5. Vachon ML, Dieterich DT. Gastrointestinal disorders in HIV including diarrhoea. Sande's HIV/AIDS medicine: medical management of AIDS. 2012.
6. Esimai BN, Obeagu EI. Prevalence of Isolated Agent in Diarrheal Infections of Children O-3 Years in Anambra State in Relation to Sex: A Survey of Five Rural Communities. J Biomed Sci. 2022;11(8):73. links/630c87eb1ddd447021194fca/Prevalence-of-Isolated-Agent-in-Diarrheal-Infections-of-Children-O-3-Years-in-Anambra-State-in-Relation-to-Sex-A-Survey-of-Five-Rural-Communities.pdf.
7. Ezimah UA, Obeagu EI, Ezimah CO, Ezimah A, Nto NJ. Diarrhoeal diseases of acquired immunodeficiency syndrome stimulate more depletion of total antioxidant status. Int. J. Adv. Multidiscip. Res. 2016;3(4):23-5. links/592bb593aca27295a80b964c/International-Journal-of-Advanced-Multidisciplinary-Research-IJAMR-Diarrhoeal-diseases-of-acquired-immunodeficiency-syndrome-stimulate-more-depletion-of-total-antioxidant-status.pdf.
8. Ojo BO, Abdulrahman OA, Haassan AO, Obeagu EI, Olamijuwon PB, Oyeromi BO, Oluwanisola DO, Kelvin U. Plasmid Profiling of Bacteria Associated with Gastroenteritis among Children in Owo, Ondo State. Asian Journal of Research and Reports in Gastroenterology. 2022 ;6(2):29-41.
9. Obeagu GU, Obeagu EI. Diarrhoea disease: A dangerous childhood disease. CPQ Women Child Health. 2019;1(6):01-8.

Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

10. Ogbu IS, Okafor EO, Obeagu EI, Ogbu CC, Esimai BN, Okeke NJ, Ukeekwe CO. Effect of Oral Administration of the Leaf Extract of Uvaria chamae (Mmimi Ohia) in Albino Wistar Rats. Journal of Pharmaceutical Research International. 2020;32(24):52-56.
11. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
12. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
13. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
14. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
15. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
16. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
17. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
18. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
19. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
20. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
21. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.

Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

22. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
23. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
24. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
25. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
26. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
27. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
28. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
29. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
30. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in

Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005

31. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8): e1450.
32. Obeagu EI, Obeagu GU, Habimana JB. Iron Deficiency Anaemia in Children. International Research in Medical and Health Sciences. 2023;6(4):26-32.
33. Ifeanyi OE, Chibunna OM, Braxton NA, Uche EC. Impact of Plasmodium falciparum malaria and hookworm infection on anaemia among pregnant women of ikwuano local government area, Abia state, Nigeria. Int J Curr Microbiol Appl Sci. 2014;3(1):104-1.
34. Ifeanyi OE. A review on free radicals and antioxidants. Int. J. Curr. Res. Med. Sci. 2018;4(2):123-33.DOI: 10.22192/ijcrms.2018.04.02.019
35. Nwandkor UU, Ifeanyi OE. Bacteriological assessment of different borehole drinking water sources in Umuahia Metropolis. International Journal of Current Microbiology and Applied Sciences. 2015;4(5):1139-50. links/5712132008ae39beb87a2ee4/Bacteriological-Assessment-of-Different-Borehole-Drinking-Water-Sources-in-Umuahia-Metropolis.pdf.
36. Stella EI, Ifeanyi OE. A review on salmonella species and indicator organisms in drinking water. Int J Compr Res Biol Sci. 2018;5(2):5-23. *DOI: http://dx.doi.org/10.22192/ijcrbs.2018.05.02.002*
37. Ugwuzor NU, Ifeanyi OE, Onyenweaku FC. Bacteriolcgical Assessment of Stream Drinking Water from various Sources in Umuahia Metropolis. World Journal of Pharmaceutical Research. 2015;4(6):122-137.
38. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
39. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
40. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
41. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
42. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-

based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.

43. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
44. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
45. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
46. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
47. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
48. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
49. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
50. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at

Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
51. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
52. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
53. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
54. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
55. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
56. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
57. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
58. Zino L, Kingma JS, Marzolini C, Richel O, Burger DM, Colbers A. Implications of bariatric surgery on the pharmacokinetics of antiretrovirals in people living with HIV. Clinical pharmacokinetics. 2022;61(5):619-635.
59. Kaip EA, Nguyen NY, Cocohoba JM. Antiretroviral therapy efficacy post-bariatric weight loss surgery: a case series of persons living with human immunodeficiency virus. Obesity Surgery. 2022;32(5):1523-1530.
60. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.

Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

61. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
62. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
63. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
64. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
65. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
66. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
67. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
68. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
69. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
70. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
71. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.

Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

72. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
73. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
74. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
75. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
76. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
77. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
78. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
79. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
80. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
81. Obeagu EI. Effects of Long-Term Omeprazole Use on Red Blood Cells: A Review. Elite Journal of Medica Science. 2024;2(1):44-52.
82. Onyeaghala EO, Maxwel EA, Obeagu EI, Hassan AO. Assessment of the Problems Associated with the use of Public Latrine System in Ife-North Local Government, Osun State, Nigeria. RESEARCH IN MEDICAL SCIENCES (NIJRMS). 2024;5(1).
83. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
84. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.

Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

85. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
86. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
87. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
88. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
89. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
90. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
91. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
92. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
93. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
94. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
95. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
96. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
97. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
98. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
99. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
100. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
101. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.

Citation: Obeagu EI. Exploring the Role of Antacids in the Prevention and Management of Gastrointestinal Complications in HIV Patients: A Review. Elite Journal of HIV, 2024; 2(3): 55-68

102. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
103. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
104. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
105. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
106. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
107. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).